Development of a technology for determining eligibility for boron neutron capture therapy (BNCT) using 18F-FBPA PET
First written in FY2021. 8 of 12 entries say "Advanced", first in FY2023-Q1. Latest entry: 2026-10-01.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「The trial also incorporates an [18F]FBPA-PET examination before BNCT to determine whether BNCT is appropriate, which is expected to enable consideration of the optimal treatment for each patient in the future.」
The Phase I/II trial for thoracic malignant tumors moved to the stage of incorporating BNCT eligibility assessment using 18F-FBPA-PET. - FY2025-H1AdvancedAnnual report
「The Company submitted a clinical trial notification for a domestic Phase I/II clinical trial combining 18F-FBPA-PET and BNCT for unresectable recurrent thoracic malignant tumors for which standard treatment is difficult to administer, and in September 2024 entered into an agreement with the National Cancer Center, Japan, SHI and 株式会社CICS concerning the conduct of the clinical trial.」
For BNCT evaluation and indication expansion using 18F-FBPA-PET, the Company proceeded to submit a clinical trial notification and conclude an implementation agreement for a domestic Phase I/II trial for thoracic malignant tumors. - FY2023-Q2RestatedAnnual report
「In Japan, the Company also entered into an agreement to cooperate in an investigator-initiated specified clinical study aimed at more accurately assessing the efficacy of BNCT in treating recurrent malignant glioma using PET (positron emission tomography) scans, and」
The Company continues to describe its cooperation agreement for the investigator-initiated specified clinical study evaluating BNCT efficacy using PET scans. - FY2023-Q1AdvancedAnnual report
「In Japan, the Company also entered into an agreement to cooperate in an investigator-initiated specified clinical study aimed at more accurately assessing the efficacy of BNCT in treating recurrent malignant glioma using a new evaluation method involving PET (positron emission tomography) scans, and」
The cooperation agreement for the investigator-initiated specified clinical study evaluating BNCT efficacy using PET scans moved to the contracting stage. - FY2022RestatedAnnual report
「As part of its BNCT expansion strategy, the Company is also jointly developing the PET drug used for 18F-FBPA-PET with an accelerator manufacturer.」
Joint development of the PET drug for 18F-FBPA-PET related to expanding BNCT indications continues. - FY2021First statedAnnual report
「As part of its BNCT expansion strategy, the Company is also jointly developing the PET drug used for 18F-FBPA-PET with an accelerator manufacturer. Going forward, development of 18F-FBPA-PET will play an important role in expanding the diseases eligible for BNCT.」
The Company is developing a diagnostic technology that visualizes the location and extent of tumors and uptake of the boron drug, enabling treatment efficacy to be predicted in advance.